Dashboard
Manage Tickers

CATX


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

b-riley-securities-maintains-buy-on-perspective-therapeutics-lowers-price-target-to-11
B. Riley Securities Maintains Buy on Persp...
11/18/2025 16:57:44

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the price target f...

perspective-therapeutics-q3-eps-035-misses-033-estimate-sales-209000k-miss-223833k-estimate
Perspective Therapeutics Q3 EPS $(0.35) Mi...
11/10/2025 21:06:10

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate...

earnings-scheduled-for-november-10-2025
Earnings Scheduled For November 10, 2025
11/10/2025 11:12:02

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
10/20/2025 18:39:30

perspective-therapeutics-reports-44-confirmed-response-rate-and-875-progression-free-patients-treated-with-212pbvmt--net-at-esmo-congress-2025
Perspective Therapeutics Reports 44% Confi...
10/20/2025 08:34:30

Updated interim results with an additional ~19 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-t...

btig-reiterates-buy-on-perspective-therapeutics-maintains-14-price-target
BTIG Reiterates Buy on Perspective Therape...
10/13/2025 13:57:29

BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
10/10/2025 17:06:47

this-aptiv-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-friday
This Aptiv Analyst Begins Coverage On A Bu...
10/10/2025 13:25:06

btig-initiates-coverage-on-perspective-therapeutics-with-buy-rating-announces-price-target-of-14
BTIG Initiates Coverage On Perspective The...
10/10/2025 10:26:24

BTIG analyst Jeet Mukherjee initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Buy rating and announces Pric...

hc-wainwright--co-reiterates-buy-on-perspective-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Pers...
10/03/2025 11:33:35

HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...

perspective-therapeutics-announces-first-patient-treated-with-psv359-in-second-cohort-of-phase-12a-dose-finding-trial-to-determine-safety-and-preliminary-anti-tumor-activity
Perspective Therapeutics Announces First P...
10/02/2025 11:03:40

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that...

hc-wainwright--co-reiterates-buy-on-perspective-therapeutics-maintains-10-price-target
HC Wainwright & Co. Reiterates Buy on Pers...
09/19/2025 11:32:47

HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $10 pr...

perspective-therapeutics-says-first-patient-dosed-in-new-cohort-of-phase-12a-trial-evaluating-the-safety-of-212pbvmt01
Perspective Therapeutics Says First Patien...
09/15/2025 11:08:23

First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi single agent dose Cohort re-ope...

perspective-therapeutics-names-joel-sendek-cfo-as-juan-graham-departs
Perspective Therapeutics Names Joel Sendek...
09/04/2025 11:24:45

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pion...

perspective-therapeutics-q2-eps-030-inline-sales-290000k-beat-154455k-estimate
Perspective Therapeutics Q2 EPS $(0.30), I...
08/13/2025 10:47:56

Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. T...

Core News & Articles
Earnings Scheduled For August 13, 2025
08/13/2025 08:32:30

a-look-ahead-perspective-therapeuticss-earnings-forecast
A Look Ahead: Perspective Therapeutics's E...
08/12/2025 20:02:48

perspective-therapeutics-to-present-updated-212pbvmt--net-cancer-therapy-data-at-esmo-congress-2025
Perspective Therapeutics To Present Update...
07/24/2025 16:46:42

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company pion...

b-riley-securities-maintains-buy-on-perspective-therapeutics-raises-price-target-to-12
B. Riley Securities Maintains Buy on Persp...
06/23/2025 18:05:32

B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target f...

wedbush-reiterates-outperform-on-perspective-therapeutics-maintains-11-price-target
Wedbush Reiterates Outperform on Perspecti...
06/23/2025 13:40:12

Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION